BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Taiwan's Advanced Biomed launch next-gen platform for precision medicine and drug discovery

19 September 2025 | News

A+PerfusC™ – Integrated Perfusion 3D Cell Culture all?in?one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro



Advanced Biomed Inc. a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, announced the launch of its A+PerfusC™ system, a compact, all?in?one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.

The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real?time observation. The system supports up to 12 days of continuous, hands?free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability.

A+PerfusC™ system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established.

Dr. Yi Lu, CEO of the Company, commented: “Traditional static cell culture often leads to uneven nutrient delivery and waste buildup, compromising cell growth, viability, and reproducibility. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste can rapidly accumulate inside the micro-grooves, requiring more frequent medium replacement which can be labor-intensive to preserve culture quality.”